Business Context and Reporting Period
This Form 8-K Current Report was filed by GRI Bio, Inc. on December 20, 2024. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in La Jolla, California. Its common stock trades on the Nasdaq Capital Market under the symbol "GRI".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on a corporate action regarding an equity offering program.
Material Changes
The Company filed a prospectus supplement to increase the maximum number of shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated May 20, 2024. The key details of this change include:
- Additional Offering Capacity: The Company increased the aggregate gross sales price limit for new shares to $322,468.
- Prior Sales: This increase is in addition to approximately $3,604,683 in shares already sold under the Sales Agreement to date.
- Legal Opinion: An opinion regarding the legality of the issuance and sale of these shares was provided by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or an outlook for future periods. No specific risks or contingencies were disclosed in this report other than the standard legal opinion regarding the share issuance.
Investor Verification Checklist
- Verify the current market price of GRI Bio common stock to assess the potential dilution impact of the additional $322,468 offering capacity.
- Review the full text of the prospectus supplement and the Sales Agreement to understand the terms of the At The Market Offering.
- Confirm the total number of shares sold to date under the Sales Agreement by cross-referencing with recent 10-Q or 10-K filings.
- Check for any subsequent filings regarding the actual sale of shares under this increased capacity.